BPC-157 + TB-500 is a synergistic blend of two potent bioregulatory peptides. This combination is designed to maximize the healing and recovery of injured tissues, leveraging the angiogenic properties of BPC-157 and the cell migration and repair potential of TB-500.
Format studied in literature: Lyophilized blend vial (5mg BPC-157 + 5mg TB-500).
There are no research or clinical studies currently available where both TB-500 and BPC-157 were used in the same experiment or presented in combination, using the same test model. However, listed below are studies observing the potential action of the individual peptides.
In a study with Tβ4 conducted in 1999,(9) experimentally wounded murine models were used as subjects, where half of the murine models were presented with saline solution and the rest were presented with peptide TB-500. The main objective of this study was to determine the peptide's potential tissue repair action. Four days after the experiment, researchers reported that murine models presented with TB-500 showed an apparent 41% increase in the re-epithelialization process (i.e., formation of new epithelial cells to resurface the wound). After seven days, wounds presented with TB-500 had allegedly contracted by at least 11% compared to saline wounds. The authors commented that 'these results suggest that Tβ4 is a potent wound healing factor with multiple activities...'
In another clinical trial from 2006,(10) 72 test subjects with pressure ulcers were presented with TB-500. The main objective of this randomized, double-blind study was to establish the potential of thymosin beta 4 (analogous to TB-500) in the presence of ulcers. The test subjects were divided into two groups, where one group was presented with a placebo for 84 days and the rest were presented daily with various concentrations of the peptide, for up to 84 days. After 84 days, there was an occurrence of the wound healing process where the ulcers exhibited signs of healing.
In a BPC-157 study,(11) three experimental murine models were used as subjects where all were experimentally wounded, with acute or chronic wounds. These murine models were then divided into two groups, where one was presented with a placebo compound and the other was presented with peptide BPC-157. After the experiment, all murine models were examined histologically, and it was determined that the murine models with BPC-157 exhibited a prominently higher number of collagen and blood vessels formed compared to the placebo murine models.
In a study,(12) the medial collateral ligament (MCL) of murine models was transected (cut through) during surgery. All murine models were then presented with a fibrin sealant agent, where some murine models were also presented with thymosin beta 4 (TB-500). Four weeks after surgery, researchers reported that healing tissues in the peptide murine models exhibited apparently formed and uniformly spaced collagen cells. The collagen cells formed in the peptide murine models were allegedly wider compared to control murine models. Additionally, mechanical properties of regenerating tissues, including femur-medial collateral ligament-tibia complexes, appeared to improve in the TB-500 group compared to control.
Another research article indicated that BPC-157 might play a role in aiding connective tissue recovery, potentially promoting tendon explant growth. Interestingly, the study suggested that BPC-157 possibly improves these cells' resistance against oxidative stress. This result could be related to F-actin formation activation, as indicated by FITC-phalloidin staining. BPC-157 also appeared to improve in vitro movement of tendon fibroblasts as indicated by a transwell filter migration test. Furthermore, BPC-157 appeared to accelerate tendon fibroblast dispersal across culture plates. Moreover, the study delved into the possible role of the FAK-paxillin pathway (a pair of proteins linked to focal adhesion that transmit signals after integrins) in transmitting BPC-157 action. Western blot tests hinted that phosphorylation rates of both FAK and paxillin appeared to increase with BPC 157, however, total protein amounts remained constant.(8)
A study(13) was conducted in murine models with experimentally injured gastrocnemius muscle complex. These murine models were initially presented with corticosteroids, which allegedly contributed to severe muscle damage in these murine models. These murine models were then divided into two groups, where one was presented with placebo and the other with BPC-157 daily for up to 14 days. After the experiment, it was reported that BPC-157 murine models appeared to exhibit complete restoration of their gastric muscles along with full ability to function. While the placebo-treated group did not exhibit any apparent change in damaged muscles.
TB-500 may also have a potential effect on muscle cell regeneration, more specifically on heart muscle cells. A study suggests that TB-500 appears to reinforce myocardial resistance under low oxygen conditions, and apparently fosters angiogenesis, possibly paving the way for cardiac cell repair. Researchers have hinted at a potential process where cardiac fibroblasts transition into cells resembling cardiomyocytes.(14) Ultimately, scholars observed that TB-500, when paired with cardiac reprogramming techniques, could collaboratively reduce potential damage to heart cells and foster their regeneration by activating inherent cells within the cardiac region. An examination using coronary artery ligation murine models appeared to exhibit results implying that TB-500 could elevate integrin-linked kinase (ILK) and protein kinase B operations in the heart, possibly increasing early cardiomyocyte resistance and apparently improving cardiac performance.(15) Experts also suggested that TB-500 could support myocardial and endothelial cell movement in the fetal heart and maintains this capability in mature cardiomyocytes.
